Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer

References

• Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust T, Tervonen H, Thursfield V, Ransom D, Shack L, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20(11):1493–9. doi:10.1016/s1470-2045(19)30456-5.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Manji GA, Olive KP, Saenger YM, Oberstein P. Current and emerging therapies in metastatic pancreatic cancer. Clin Cancer Res. 2017;23(7):1670–8. doi:10.1158/1078-0432.Ccr-16-2319.
   PubMed Web of Science ®Google Scholar
• Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet (London, England). 2020;395(10242):2008–20. doi:10.1016/s0140-6736(20)30974-0.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1–Positive non–small-Cell lung cancer. N Engl J Med. 2016;375(19):1823–33. doi:10.1056/NEJMoa1606774.
   PubMed Web of Science ®Google Scholar
• Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–62. doi:10.1016/s0140-6736(17)31601-x.
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet (London, England). 2019;393(10167):156–67. doi:10.1016/s0140-6736(18)31999-8.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, et al. Safety and efficacy of Pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013. doi:10.1001/jamaoncol.2018.0013.
   PubMed Web of Science ®Google Scholar
• Weiss GJ, Waypa J, Blaydorn L, Coats J, McGahey K, Sangal A, Niu J, Lynch CA, Farley JH, Khemka V. A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). Br J Cancer. 2017;117(1):33–40. doi:10.1038/bjc.2017.145.
   PubMed Web of Science ®Google Scholar
• Padrón LJ, Maurer DM, O’Hara MH, O’Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 2022;28(6):1167–77. doi:10.1038/s41591-022-01829-9.
   PubMed Web of Science ®Google Scholar
• Bockorny B, Grossman JE, Hidalgo M. Facts and hopes in immunotherapy of pancreatic cancer. Clin Cancer Res. 2022;28(21):4606–17. doi:10.1158/1078-0432.Ccr-21-3452.
   PubMed Web of Science ®Google Scholar
• Li X, Gulati M, Larson AC, Solheim JC, Jain M, Kumar S, Batra SK. Immune checkpoint blockade in pancreatic cancer: trudging through the immune desert. Semin Cancer Biol. 2022;86(Pt 2):14–27. doi:10.1016/j.semcancer.2022.08.009.
   PubMedGoogle Scholar
• André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, et al. Pembrolizumab in microsatellite-Instability–High advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–18. doi:10.1056/NEJMoa2017699.
   PubMed Web of Science ®Google Scholar
• Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria JC, Ferté C. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol. 2018;15(12):748–62. doi:10.1038/s41571-018-0111-2.
   PubMed Web of Science ®Google Scholar
• Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, et al. Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018;4(11):1543–52. doi:10.1001/jamaoncol.2018.3676.
   PubMed Web of Science ®Google Scholar
• Ferté C, Fernandez M, Hollebecque A, Koscielny S, Levy A, Massard C, Balheda R, Bot B, Gomez-Roca C, Dromain C, et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res. 2014;20(1):246–52. doi:10.1158/1078-0432.Ccr-13-2098.
   PubMed Web of Science ®Google Scholar
• Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, et al. Comparison of fast-progression, hyperprogressive disease, and early deaths in advanced non–small-Cell lung cancer treated with PD-1/PD-L1 inhibitors or chemotherapy. JCO Precis Oncol. 2020;4(4):829–40. doi:10.1200/po.20.00021.
   PubMedGoogle Scholar
• Sasaki A, Nakamura Y, Mishima S, Kawazoe A, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, et al. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer. 2019;22(4):793–802. doi:10.1007/s10120-018-00922-8.
   PubMed Web of Science ®Google Scholar
• Klemen ND, Hwang S, Bradic M, Rosenbaum E, Dickson MA, Gounder MM, Kelly CM, Keohan ML, Movva S, Thornton KA, et al. Long-term follow-up and patterns of response, progression, and hyperprogression in patients after PD-1 blockade in advanced Sarcoma. Clin Cancer Res. 2022;28(5):939–47. doi:10.1158/1078-0432.Ccr-21-3445.
   PubMed Web of Science ®Google Scholar
• Saâda-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, Even C, Fayette J, Guigay J, Loirat D, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28(7):1605–11. doi:10.1093/annonc/mdx178.
   PubMed Web of Science ®Google Scholar
• Matos I, Martin-Liberal J, García-Ruiz A, Hierro C, Ochoa de Olza M, Viaplana C, Azaro A, Vieito M, Braña I, Mur G, et al. Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria. Clin Cancer Res. 2020;26(8):1846–55. doi:10.1158/1078-0432.Ccr-19-2226.
   PubMed Web of Science ®Google Scholar
• Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC, et al. Hyperprogressive disease is a New pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017;23(8):1920–8. doi:10.1158/1078-0432.Ccr-16-1741.
   PubMed Web of Science ®Google Scholar
• Kas B, Talbot H, Ferrara R, Richard C, Lamarque JP, Pitre-Champagnat S, Planchard D, Balleyguier C, Besse B, Mezquita L, et al. Clarification of definitions of hyperprogressive disease during immunotherapy for non–small cell lung cancer. JAMA Oncol. 2020;6(7):1039–46. doi:10.1001/jamaoncol.2020.1634.
   PubMed Web of Science ®Google Scholar
• Nimmakayala RK, Seshacharyulu P, Lakshmanan I, Rachagani S, Chugh S, Karmakar S, Rauth S, Vengoji R, Atri P, Talmon GA, et al. Cigarette smoke induces stem cell features of pancreatic cancer cells via PAF1. Gastroenterology. 2018;155(3):892–908.e896. doi:10.1053/j.gastro.2018.05.041.
   PubMed Web of Science ®Google Scholar
• Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, Heyd B, Cleau D, d’Engremont C, Dupont-Gossart AC, et al. Overall survival prediction and usefulness of second-line chemotherapy in advanced pancreatic adenocarcinoma. J Natl Cancer Inst. 2017;109(10). doi:10.1093/jnci/djx037.
   PubMedGoogle Scholar
• Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021;27(1):152–64. doi:10.1038/s41591-020-1131-x.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56–93. doi:10.1093/cid/cir073.
   PubMed Web of Science ®Google Scholar
• Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971;284(19):1061–5. doi:10.1056/nejm197105132841904.
   PubMed Web of Science ®Google Scholar
• Galloway-Peña JR, Jenq RR, Shelburne SA. Can consideration of the microbiome improve antimicrobial utilization and treatment outcomes in the oncology patient? Clin Cancer Res. 2017;23(13):3263–8. doi:10.1158/1078-0432.Ccr-16-3173.
   PubMed Web of Science ®Google Scholar
• Ochi N, Ichihara E, Takigawa N, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Oda N, et al. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression. Eur J Cancer (Oxford, England: 1990). 2021;149:73–81. doi:10.1016/j.ejca.2021.02.040.
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, Brock C, Power D, Hatcher O, Falconer A, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019;5(12):1774–8. doi:10.1001/jamaoncol.2019.2785.
   PubMed Web of Science ®Google Scholar
• Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007;1(1):56–66. doi:10.1038/ismej.2007.3.
   PubMed Web of Science ®Google Scholar
• Poizeau F, Kerbrat S, Balusson F, Tattevin P, Revest M, Cattoir V, Luque-Paz D, Lesimple T, Pracht M, Dinulescu M, et al. The Association between antibiotic use and outcome among metastatic melanoma patients receiving immunotherapy. JNCI. 2022;114(5):686–94. doi:10.1093/jnci/djac019.
   PubMedGoogle Scholar
• Bosco MC, D’Orazi G, Del Bufalo D. Targeting hypoxia in tumor: a new promising therapeutic strategy. J Exp Clin Cancer Res. 2020;39(1):8. doi:10.1186/s13046-019-1517-0.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wen S, Xia J, Du X, Wu Y, Pan B, Zhu W, Shen B. Association of dynamic changes in peripheral blood indexes with response to PD-1 inhibitor-based combination therapy and survival among patients with advanced non-small cell lung cancer. Front Immunol. 2021;12:672271. doi:10.3389/fimmu.2021.672271.
   PubMed Web of Science ®Google Scholar
• Sui Q, Zhang X, Chen C, Tang J, Yu J, Li W, Han K, Jiang W, Liao L, Kong L, et al. Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer. Nat Commun. 2022;13(1):7316. doi:10.1038/s41467-022-35096-6.
   PubMed Web of Science ®Google Scholar
• Kim CG, Kim KH, Pyo KH, Xin CF, Hong MH, Ahn BC, Kim Y, Choi SJ, Yoon HI, Lee JG, et al. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol. 2019;30(7):1104–13. doi:10.1093/annonc/mdz123.
   PubMed Web of Science ®Google Scholar